On the night of November 19, 2023, Qingdao Qingdao Baheal Medical Inc. ("Baheal Medical", 301015.SZ) announced it has entered into landmark commercialization agreements with Guangdong RADIO Pharma Technology Co., Ltd. ("Radio") and Beijing Medis Medical Technology Co., Ltd. ("Medis Medical"). With these agreements, Baheal Medical will exclusively commercialize a portfolio of radio-pharmaceuticals in mainland China, which include Radio's innovative class 1 nuclear medical oncology diagnostic drug, 99mTc-3PRGD2, along with a range of imaging products such as SPECT. In addition, Baheal Medical will also exclusively manage the commercial operations of Medis Medical’s Electromagnetic Localization Puncture Guidance Device and associated products for ultrasound applications.

"The year 2023 marks a decade since the proposal of the Belt and Road Initiative. Throughout this period, Baheal Pharma Group has effectively utilized its prominence within the medical health sector to actively engage with and contribute towards it. Capitalizing on its industry resources, Baheal has been instrumental in revving up growth across participating countries and regions through the provision of high-quality medical health services. As the 10th anniversary of the initiative draws near, Baheal remains deeply committed, taking part in crucial events and making significant contributions to the construction of the Belt and Road with tangible actions.

"On September 28, 2023, Qingdao Baheal Pharmaceutical Co., Ltd., a subsidiary of Shanghai Baheal Medical Co., Ltd., officially held a groundbreaking ceremony for the third phase of its production workshop and supporting construction projects. The event was attended by representative leaders from Jimo District Government of Qingdao city, provincial drug administration, Chairman Fu Gang of Baheal Pharma Group, General Manager Zhuo Yueqiang of Shanghai Xinchangning Group, directors of Baheal Pharma Group, and Zhu Xiaowei, Chairman of BAHEAL Pharmaceutical Co., Ltd. among other distinguished guests, as well as contractors and employees of Qingdao Baheal BAHEAL Pharmaceutical Co., LTD.

On September 22, 2023, the World Federation of Chinese Doctors and Baheal Pharmaceutical Group jointly initiated the 2023 World Chinese Physicians Conference and the Medical Innovation and Translation Forum in Qingdao, Shandong. This gathering, the first grand ceremony since the pandemic, brought together numerous exceptional representatives of Chinese doctors and scholars from both home and abroad to share the latest accomplishments and innovative trends in global healthcare. As a critical part of this forum, the Baheal Pharmaceutical Group, witnessed by a multitude of experts and academics, signed a contract with Professor Wang Wei, the Vice President of the World Federation of Chinese Doctors and Deputy Principal of Edith Cowan University (ECU) in Australia. They will collaborate to establish a research platform in the realm of glycomics.

On August 21, 2023, Qingdao Baheal Pharmaceutical Co., Ltd. (referred to as "Baheal Pharmaceutical", 301015.SZ) and Gilead (Shanghai) Pharmaceutical Technology Co., Ltd. (referred to as "Gilead Sciences") signed a strategic cooperation agreement. Representatives from both companies, including Jin Fangqian, Global Vice President and General Manager of Gilead Sciences China, and Fu Gang, Chairman of Baheal Pharmaceutical, attended the signing ceremony.